Studies from National Heart Lung and Blood Institute (NHLBI) Update Current Data on Psoriasis (Boosting Nad Preferentially Blunts Th17 Inflammation Via Arginine Biosynthesis and Redox Control In Healthy and Psoriasis Subjects).
In: Genomics & Genetics Weekly, 2023-11-17, S. 1801-1801
serialPeriodical
Zugriff:
A recent study conducted by the National Heart Lung and Blood Institute (NHLBI) in Bethesda, Maryland, explored the effects of nicotinamide adenine dinucleotide-positive (NAD+) boosting on psoriasis. The researchers found that nicotinamide riboside (NR) supplementation reduced the secretion of interferon g (IFNg) and interleukin (IL)-17, particularly affecting T helper (Th) 17 polarization. The study also revealed that NR administration increased antioxidant defenses in CD4+ T cells and attenuated Th17 immune responsiveness. These findings suggest that NAD+ boosting may have potential therapeutic benefits for CD4+ T cell-linked inflammation. [Extracted from the article]
Copyright of Genomics & Genetics Weekly is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Studies from National Heart Lung and Blood Institute (NHLBI) Update Current Data on Psoriasis (Boosting Nad Preferentially Blunts Th17 Inflammation Via Arginine Biosynthesis and Redox Control In Healthy and Psoriasis Subjects).
|
---|---|
Zeitschrift: | Genomics & Genetics Weekly, 2023-11-17, S. 1801-1801 |
Veröffentlichung: | 2023 |
Medientyp: | serialPeriodical |
ISSN: | 1531-6467 (print) |
Schlagwort: |
|
Sonstiges: |
|